cancer cells and Enhance Efficacy
Next Generation ADC Platform
PINOT-ADC™ is a next-generation ADC anticancer drug platform technology that uses an independent drug (Payload) and linker
that overcome the limitations of existing ADC drugs.
Based on the PINOT-ADC™ technology, we are jointly conducting research and development of a number of candidate substances such as the best-in-class ADC anticancer drug (PBX-001) targeting solid cancer Trop2 with various partner companies.
Distinction and Competitive Advantage
Use of new payload or overcoming resistance
- More than 5 to 10 times stronger pharmacological effect than Camptothecin drugs such as SN38
- Safe even when administered alone plus with a wide therapeutic window secured
Overcoming resistance related to ADC processing through rapid release around cancer tissue
- Use of a linker system with high release efficiency in cancer tissues with the use of a high safety payload
- Maximizing anticancer efficacy by disseminating the drug to cancer cells after drug release not only inside cancer cells but also around cancer tissues